HHS awards $211M R&D contract to Chimerix for smallpox antiviral, raising value-for-money questions

Contract Overview

Contract Amount: $211,409,788 ($211.4M)

Contractor: Emergent Biodefense Operations Lansing LLC

Awarding Agency: Department of Health and Human Services

Start Date: 2022-08-29

End Date: 2028-10-01

Contract Duration: 2,225 days

Daily Burn Rate: $95.0K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: R&D

Official Description: CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL

Place of Performance

Location: DURHAM, DURHAM County, NORTH CAROLINA, 27713

State: North Carolina Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $211.4 million to EMERGENT BIODEFENSE OPERATIONS LANSING LLC for work described as: CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL Key points: 1. Contract awarded on a sole-source basis, limiting price competition and potentially increasing costs. 2. The contract's duration of over 5 years suggests a long-term commitment to research and development. 3. Focus on smallpox antiviral research aligns with national biodefense priorities. 4. The fixed-price contract type aims to control costs, but the lack of competition is a concern. 5. Performance is in North Carolina, potentially impacting the local economy and workforce. 6. The contract is for R&D in Biotechnology, a critical but often high-cost sector.

Value Assessment

Rating: questionable

The contract value of $211.4 million for R&D in biotechnology is substantial. Without a competitive bidding process, it is difficult to benchmark the pricing against market rates or similar contracts. The sole-source award raises concerns about whether the government secured the best possible value. Further analysis would be needed to determine if the pricing is reasonable given the scope of work and the contractor's capabilities.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning it was not competed. This typically occurs when only one vendor can provide the required goods or services, or in cases of urgent need. The lack of competition means there were no other bidders to drive down prices through a bidding war, potentially leading to a higher cost for the government.

Taxpayer Impact: Sole-source awards limit the government's ability to leverage competition to achieve lower prices, potentially resulting in higher taxpayer expenditure for this research and development effort.

Public Impact

The primary beneficiary is the Department of Health and Human Services (HHS) in its mission to protect public health. The contract supports the development of a critical antiviral medication for smallpox. Geographic impact is concentrated in North Carolina, where the contractor is located. Workforce implications include employment for researchers and support staff at Chimerix Inc.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition may lead to inflated costs.
Sole-source award raises concerns about best value.
Long contract duration could expose taxpayers to prolonged higher costs if not managed effectively.

Positive Signals

Contract supports critical biodefense research.
Firm fixed-price contract type provides cost certainty.
Contractor is performing R&D in a specialized biotechnology field.

Sector Analysis

The contract falls within the Biotechnology Research and Development sector, a critical area for national security and public health. This sector is characterized by high innovation, significant investment, and often long development cycles. Comparable spending benchmarks are difficult to establish without more specific details on the R&D scope, but significant government investment in biodefense capabilities is common.

Small Business Impact

This contract does not appear to have a small business set-aside. As a sole-source award, it is unlikely that subcontracting opportunities for small businesses were explicitly mandated or sought through a competitive process. The impact on the small business ecosystem is therefore likely minimal unless the prime contractor proactively engages small businesses for subcontracting.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). Transparency is dependent on HHS's reporting practices. Inspector General jurisdiction would apply if any fraud, waste, or abuse is suspected.

Related Government Programs

Biodefense Advanced Research Projects Agency (BARDA) funding
Strategic National Stockpile (SNS) procurements
National Institutes of Health (NIH) research grants
Department of Defense (DoD) biosecurity programs

Risk Flags

Sole-source award
Lack of competitive bidding
Potential for cost overruns in R&D
Uncertainty of R&D outcomes

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $211.4 million to EMERGENT BIODEFENSE OPERATIONS LANSING LLC. CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL

Who is the contractor on this award?

The obligated recipient is EMERGENT BIODEFENSE OPERATIONS LANSING LLC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $211.4 million.

What is the period of performance?

Start: 2022-08-29. End: 2028-10-01.

What is Chimerix Inc.'s track record with government contracts, particularly in R&D for antivirals?

Chimerix Inc. has a history of developing antiviral therapies. Their most notable product, brincidofovir, received FDA approval for treating smallpox. While this specific contract is a sole-source award, the company's prior experience in developing and seeking approval for a smallpox antiviral suggests a relevant track record. However, a deeper dive into their past performance on government contracts, including any issues or successes, would be necessary for a comprehensive assessment. Information on past contract performance metrics, delivery timeliness, and adherence to quality standards would be crucial.

How does the $211.4 million value compare to similar R&D contracts for antivirals?

Benchmarking this $211.4 million contract is challenging without more granular data on the specific R&D activities and milestones. However, the development of novel therapeutics, especially for biodefense applications like smallpox, is inherently expensive and time-consuming. Government investments in such areas can range from tens to hundreds of millions of dollars, depending on the stage of development, complexity of the research, and the number of candidates pursued. The sole-source nature of this award prevents a direct price comparison with competitively awarded contracts for similar R&D, making it difficult to definitively assess if this represents a fair market price.

What are the primary risks associated with this sole-source R&D contract?

The primary risks associated with this sole-source contract are related to cost and competition. Without a competitive bidding process, there's a heightened risk that the government may not be achieving the best possible price for the R&D services. This lack of competition can also reduce the incentive for the contractor to innovate or perform at peak efficiency. Furthermore, R&D inherently carries scientific risk; the project may not yield the desired antiviral results within the projected timeline or budget. Ensuring robust oversight and clear performance metrics will be critical to mitigating these risks.

How effective is the firm fixed-price contract type in managing R&D costs for this specific antiviral development?

A firm fixed-price (FFP) contract type is generally preferred by the government for its cost control benefits, as it shifts most of the cost risk to the contractor. For R&D, FFP can be effective if the scope of work is well-defined and the milestones are clear. However, R&D is inherently uncertain, and a poorly defined scope can lead to change orders or disputes, potentially negating the cost-saving benefits of FFP. In this case, the success of FFP will depend on how precisely the R&D objectives and deliverables are articulated in the contract and whether the contractor can meet them without significant unforeseen challenges.

What are the historical spending patterns for smallpox antiviral R&D by HHS?

HHS, particularly through agencies like the Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA), has historically invested significantly in biodefense countermeasures, including antivirals for diseases like smallpox. Spending in this area can fluctuate based on perceived threats and national priorities. While specific historical figures for smallpox antiviral R&D alone are not readily available without detailed budget analysis, it is known that substantial funds have been allocated to ensure preparedness against bioterrorism threats, which includes the development and stockpiling of effective medical countermeasures.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › General Science and Technology R&D Services

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: 75A50122R00012

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 50 SHAWMUT RD, CANTON, MA, 02021

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Limited Liability Corporation, Manufacturer of Goods, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $647,489,187

Exercised Options: $211,409,788

Current Obligation: $211,409,788

Actual Outlays: $173,882,636

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline